

April 14, 2009



Neurology Snapshot: Migraine

Event: American Academy of Neurology, April 25-May 2, 2009



Migraine Market Leaders

JNJ (NYSE:JNJ): Topamax (migraine prophylaxis)

Pfizer (NYSE:PFE): Relpax- eletriptan (acute migraine)

GSK (NYSE:GSK)/**Pozen** (NASDAQ:POZN): Treximet- sumatriptan and naproxen sodium (acute migraine)
[GSK's and Pozen's Treximet tablets effective in patients who had poor response to migraine treatment with a short-acting triptan](#)

Abbott (NYSE:ABT): Depakote (migraine prophylaxis)

Merck (NYSE:MRK): MK-0974- oral calcitonin-gene-related peptide receptor antagonist (acute migraine)
[Merck's migraine drug MK-0974 faces cautious FDA environment for label, despite lack of cardiovascular risk seen so far, experts say \(Pharmawire\)](#)
[Merck's MK0974 could become first-line treatment for migraines, physicians optimistic about Phase III results \(Pharmawire\)](#)

Allergan (NYSE:AGN): Botox- Botulinum toxin type A (chronic daily headache)
[Allergan's Botox faces reimbursement issues for use in chronic daily headache, even if approved, experts say \(Pharmawire\)](#)
[Allergan's Botox has no systemic toxicity, increases patient compliance in chronic daily headache, physicians say \(Pharmawire\)](#)
[Allergan's Botox data in chronic migraine called 'inconclusive,' concerns about cost, convenience raised - physicians \(Pharmawire\)](#)

Eisai (OTC:ESALY): perampanel- non-competitive AMPA-type glutamate receptor antagonist (migraine prophylaxis)



Unpartnered Targets in Development

Alexza Pharmaceuticals (NASDAQ:ALXA): Market cap USD 59.0m
Staccato loxapine/AZ-104 (acute migraine)
[Alexza launches Phase IIb trial of Staccato loxapine in patients with migraine headaches](#)
Company plans to submit NDA early 2010

MAP Pharmaceuticals (NASDAQ:MAPP): Market cap USD 55.63m
MAP0004- orally inhaled version of dihydroergotamine (acute migraine)
[MAP Pharmaceuticals interested in partnering its migraine compound, CEO says \(Pharmawire\)](#)
Phase III results expected December 2009

Torrey Pines (NASDAQ:TPTX): Market cap USD 2.72m
Tezampanel- targets the AMPA and kainate sub-type receptor (acute migraine)
[TorreyPines will consider partnership offers for its first-in-class migraine drug tezampanel, CEO says \(Pharmawire\)](#)

CoLucid Pharmaceuticals: Raised USD 25m in Series B Financing for migraine compound July 2008
COL-144- targets 5HT1F receptors expressed in the trigeminal nerve pathway
[CoLucid could strike deal on migraine drug next year; sale of company possible, says CEO \(Pharmawire\)](#)

NuPathe: Raised USD 30m in Series B Financing July 2008
Zelrix- transdermal formulation of sumatriptan (acute migraine)
[NuPathe expects to be a takeover target after completion of clinical trials, CEO says \(Pharmawire\)](#)

NeurAxon: Raised USD 32m in Series B Financing August 2007
NXN-188- 5-HT agonist and nNOS inhibition (acute migraine)
[NeurAxon could strike deal on migraine drug next year, CEO says; skepticism remains, industry experts say \(Pharmawire\)](#)
Phase II trial initiates May 2009